PDSB Insider Trading Activity and SEC Form 4 Filings
PDSB insider trading summary
No open-market insider purchases or sales of PDS Biotechnology Corp (PDSB) have been reported on SEC Form 4 in the past 12 months.
Latest PDSB insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Feb 28, 2025 | Stephen C. Glover | Insider | Buy | $25K (15,061 @ $1.66) |
| Feb 28, 2025 | Gregory Gene Freitag | Insider | Buy | $25K (15,060 @ $1.66) |
| Dec 13, 2021 | Matthew C Hill | Chief Financial Officer | Buy | $4K (400 @ $8.90) |
| Dec 13, 2021 | Matthew C Hill | Chief Financial Officer | Buy | $900 (100 @ $9.00) |
| Dec 13, 2021 | Matthew C Hill | Chief Financial Officer | Buy | $900 (100 @ $9.00) |
| Dec 13, 2021 | Matthew C Hill | Chief Financial Officer | Buy | $23K (2,500 @ $9.00) |
| Jun 16, 2021 | DeLyle W Bloomquist | Insider | Buy | $99K (10,000 @ $9.88) |
| Jun 15, 2021 | Voorhees Seth Van | Chief Financial Officer | Buy | $150K (17,647 @ $8.50) |
| Jun 15, 2021 | Steve C Glover | Insider | Buy | $50K (5,882 @ $8.50) |
| Jun 15, 2021 | Gregory Gene Freitag | Insider | Buy | $50K (5,882 @ $8.50) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.